-transparent.png){kind=logo}
1. Whole blood platelet aggregation was measured by electrical impedance in 28 controls and 28 patients with primary Raynaud's phenomenon. 2. The patients were entered into a double-blind, placebo-controlled cross-over trial of the calcium antagonist nisoldipine, in which they received, in random order, three, 4 week treatments with placebo and nisoldipine (5 and 10 mg day-1). 3. Platelet aggregation responses to two concentrations (5.0 and 0.5 micrograms ml-1) of collagen were determined before treatment and at the end of each treatment phase. 4. There were no differences in aggregation response to either collagen concentration between controls and patients with primary Raynaud's phenomenon, or between placebo and active treatment phases. 5. These data do not support the suggestion that nisoldipine has a significant anti-platelet effect.
J L Francis, and
O S Roath, and
V F Challenor, and
D G Waller
January 1993,
Scandinavian journal of rheumatology,
J L Francis, and
O S Roath, and
V F Challenor, and
D G Waller
July 1989,
Journal of clinical pathology,
J L Francis, and
O S Roath, and
V F Challenor, and
D G Waller
February 1991,
Journal of clinical pathology,
J L Francis, and
O S Roath, and
V F Challenor, and
D G Waller
January 1985,
Angiologia,
J L Francis, and
O S Roath, and
V F Challenor, and
D G Waller
January 1990,
European journal of clinical pharmacology,
J L Francis, and
O S Roath, and
V F Challenor, and
D G Waller
January 2011,
Journal of thrombosis and haemostasis : JTH,
J L Francis, and
O S Roath, and
V F Challenor, and
D G Waller
November 1994,
Arzneimittel-Forschung,
J L Francis, and
O S Roath, and
V F Challenor, and
D G Waller
April 2011,
Journal of thrombosis and haemostasis : JTH,
J L Francis, and
O S Roath, and
V F Challenor, and
D G Waller
December 1987,
The British journal of dermatology,
J L Francis, and
O S Roath, and
V F Challenor, and
D G Waller
February 2009,
Platelets,
